Corosolic acid attenuates platelet-derived growth factor signaling in macrophages and smooth muscle cells of pulmonary arterial hypertension
Copyright © 2024 Elsevier B.V. All rights reserved..
Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease that is characterized by vascular remodeling of the pulmonary artery. Pulmonary vascular remodeling is primarily caused by the excessive proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs), which are facilitated by perivascular inflammatory cells including macrophages. Corosolic acid (CRA) is a natural pentacyclic triterpenoid that exerts anti-inflammatory effects. In the present study, the effects of CRA on the viability of macrophages were examined using monocrotaline (MCT)-induced PAH rats and human monocyte-derived macrophages. Although we previously reported that CRA inhibited signal transducer and activator of transcription 3 (STAT3) signaling and ameliorated pulmonary vascular remodeling in PAH, the inhibitory mechanism remains unclear. Therefore, the underlying mechanisms were investigated using PASMCs from idiopathic PAH (IPAH) patients. In MCT-PAH rats, CRA inhibited the accumulation of macrophages around remodeled pulmonary arteries. CRA reduced the viability of human monocyte-derived macrophages. In IPAH-PASMCs, CRA attenuated cell proliferation and migration facilitated by platelet-derived growth factor (PDGF)-BB released from macrophages and PASMCs. CRA also downregulated the expression of PDGF receptor β and its signaling pathways, STAT3 and nuclear factor-κB (NF-κB). In addition, CRA attenuated the phosphorylation of PDGF receptor β and STAT3 following the PDGF-BB simulation. The expression and phosphorylation levels of PDGF receptor β after the PDGF-BB stimulation were reduced by the small interfering RNA knockdown of NF-κB, but not STAT3, in IPAH-PASMCs. In conclusion, CRA attenuated the PDGF-PDGF receptor β-STAT3 and PDGF-PDGF receptor β-NF-κB signaling axis in macrophages and PASMCs, and thus, ameliorated pulmonary vascular remodeling in PAH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:973 |
|---|---|
| Enthalten in: |
European journal of pharmacology - 973(2024) vom: 16. Apr., Seite 176564 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamamura, Aya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Corosolic acid |
|---|
| Anmerkungen: |
Date Revised 19.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ejphar.2024.176564 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371036933 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371036933 | ||
| 003 | DE-627 | ||
| 005 | 20240420232450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2024.176564 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM371036933 | ||
| 035 | |a (NLM)38614383 | ||
| 035 | |a (PII)S0014-2999(24)00252-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamamura, Aya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Corosolic acid attenuates platelet-derived growth factor signaling in macrophages and smooth muscle cells of pulmonary arterial hypertension |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease that is characterized by vascular remodeling of the pulmonary artery. Pulmonary vascular remodeling is primarily caused by the excessive proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs), which are facilitated by perivascular inflammatory cells including macrophages. Corosolic acid (CRA) is a natural pentacyclic triterpenoid that exerts anti-inflammatory effects. In the present study, the effects of CRA on the viability of macrophages were examined using monocrotaline (MCT)-induced PAH rats and human monocyte-derived macrophages. Although we previously reported that CRA inhibited signal transducer and activator of transcription 3 (STAT3) signaling and ameliorated pulmonary vascular remodeling in PAH, the inhibitory mechanism remains unclear. Therefore, the underlying mechanisms were investigated using PASMCs from idiopathic PAH (IPAH) patients. In MCT-PAH rats, CRA inhibited the accumulation of macrophages around remodeled pulmonary arteries. CRA reduced the viability of human monocyte-derived macrophages. In IPAH-PASMCs, CRA attenuated cell proliferation and migration facilitated by platelet-derived growth factor (PDGF)-BB released from macrophages and PASMCs. CRA also downregulated the expression of PDGF receptor β and its signaling pathways, STAT3 and nuclear factor-κB (NF-κB). In addition, CRA attenuated the phosphorylation of PDGF receptor β and STAT3 following the PDGF-BB simulation. The expression and phosphorylation levels of PDGF receptor β after the PDGF-BB stimulation were reduced by the small interfering RNA knockdown of NF-κB, but not STAT3, in IPAH-PASMCs. In conclusion, CRA attenuated the PDGF-PDGF receptor β-STAT3 and PDGF-PDGF receptor β-NF-κB signaling axis in macrophages and PASMCs, and thus, ameliorated pulmonary vascular remodeling in PAH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Corosolic acid | |
| 650 | 4 | |a Macrophage | |
| 650 | 4 | |a PDGF | |
| 650 | 4 | |a Pulmonary hypertension | |
| 650 | 4 | |a Smooth muscle | |
| 650 | 4 | |a Vascular remodeling | |
| 700 | 1 | |a Fujiwara, Moe |e verfasserin |4 aut | |
| 700 | 1 | |a Kawade, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Amano, Taiki |e verfasserin |4 aut | |
| 700 | 1 | |a Hossain, Alamgir |e verfasserin |4 aut | |
| 700 | 1 | |a Nayeem, Md Junayed |e verfasserin |4 aut | |
| 700 | 1 | |a Kondo, Rubii |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Yoshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Yasumichi |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Hidetoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Susumu |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Motohiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamura, Hisao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 973(2024) vom: 16. Apr., Seite 176564 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
| 773 | 1 | 8 | |g volume:973 |g year:2024 |g day:16 |g month:04 |g pages:176564 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2024.176564 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 973 |j 2024 |b 16 |c 04 |h 176564 | ||